| Id: | acc1703 |
| Group: | 2sens |
| Protein: | pRB |
| Gene Symbol: | RB1 |
| Protein Id: | P06400 |
| Protein Name: | RB_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser795 |
| Site Sequence: | PRSPYKFPSSPLRIPGGNIYI |
| Disease Category: | Cancer |
| Disease: | Lung Cancer |
| Disease Subtype: | NSCLC |
| Disease Cellline: | Ma-10 |
| Disease Info: | |
| Drug: | paclitaxel |
| Drug Info: | "Paclitaxel is a plant-derived alkaloid and potent antineoplastic agent that stabilizes microtubules to inhibit cancer cell division, primarily used in the treatment of ovarian, breast, and lung cancers. " |
| Effect: | sensitize |
| Effect Info: | "ERK activation and subsequent pRB phosphorylation regulate the cell cycle, making tumor cells sensitive to paclitaxel." |
| Note: | |
| Score: | 5.0 |
| Pubmed(PMID): | 15138593 |
| Sentence Index: | 15138593_6-7 |
| Sentence: | "Furthermore, PD98059 inhibited cell cycle progression during paclitaxel treatment, the accumulation of sub-G1 population, and the cytotoxic effect by paclitaxel in Ma-10 cells, suggesting that ERK activation by paclitaxel, subsequent pRB phosphorylation, and the cell cycle progression during paclitaxel treatment are important determinants of sensitivity to paclitaxel. These observations raise the possibility that the promotion of cell cycle during the exposure of lung cancer cells to paclitaxel may sensitize resistant cells to paclitaxel." |
Sequence & Structure:
MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTALCQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTELQKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSSISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYKTAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFMNSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKSNLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVKDIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDNIFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEGNLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNHTAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYLRLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLKFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLSPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQKLAEMTSTRTRMQKQKMNDSMDTSNKEEK
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| RB1-Ser795 | |
|---|---|
| Cancer | Intensity |
| BRCA | 1 |
| COAD | |
| HGSC | 1.314 |
| ccRCC | 0.252 |
| GBM | |
| HNSC | -0.957 |
| LUAD | -0.782 |
| LUSC | -0.826 |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 795 | D | Skin cancer | Phosphorylation | 23888052 |
| S | 795 | U | Melanoma | Phosphorylation | 15502804 ; 15502804 ; 15502804 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| P06400 | RB1 | P | Ser795 | SPYKFPSS(ph)PLR | A549 | Staursporin | 5.9515 | up | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A549 | Dasatinib | 6.6663 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A431 | Gefitinib | 8.5113 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A431 | Gefitinib | 6.2793 | - | |
| P06400 | RB1 | P | Ser795 | SPYKFPSS(ph)PLR | A431 | Gefitinib | 5.3028 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A431 | Gefitinib | 13.2099 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A431 | Gefitinib | 7.2478 | - | |
| P06400 | RB1 | P | Ser780;Ser788;Ser795 | TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPSS(ph)PLR | A431 | Gefitinib | 5.3441 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A431 | Gefitinib | 7.2524 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A431 | Gefitinib | 6.187 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A549 | AZD8055 | 7.7331 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A549 | Dactolisib | 8.783 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A549 | Dasatinib | 15 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A431 | Gefitinib | 2 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A549 | Dasatinib | 6.0533 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A549 | Nintedanib | 7.6768 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A549 | Pictilisib | 10.9236 | - | |
| P06400 | RB1 | P | Ser795 | SPYKFPSS(ph)PLR | A549 | Pictilisib | 6.309 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A549 | Refametinib | 15 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A549 | Refametinib | 9.4401 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A549 | Staursporin | 8.3624 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A549 | Staursporin | 6.3712 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A549 | Tideglusib | 8.7826 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A431 | Dasatinib | 12.9897 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A431 | Afatinib | 6.5269 | - | |
| P06400 | RB1 | P | Ser780;Ser788;Ser795 | TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPSS(ph)PLR | A431 | Afatinib | 6.4091 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A431 | Afatinib | 6.6331 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A431 | Afatinib | 5.4604 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A431 | Afatinib | 8.7521 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A431 | Afatinib | 8.2796 | - | |
| P06400 | RB1 | P | Ser780;Tyr790;Ser795 | TNILQYASTRPPTLS(ph)PIPHIPRSPY(ph)KFPSS(ph)PLR | A431 | Afatinib | 4.641 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A431 | Afatinib | 8.7822 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A431 | Afatinib | 6.2606 | - | |
| P06400 | RB1 | P | Ser780;Ser788;Ser795 | TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPSS(ph)PLR | A431 | Afatinib | 5.5726 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A431 | Afatinib | 9.3058 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A431 | Dasatinib | 5.4737 | - | |
| P06400 | RB1 | P | Ser795 | SPYKFPSS(ph)PLR | A431 | Dasatinib | 9.9229 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A431 | Dasatinib | 5.3155 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A431 | Dasatinib | 5.2464 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A431 | Dasatinib | 7.2486 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A431 | Dasatinib | 5.2098 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A431 | Dasatinib | 9.7313 | - | |
| P06400 | RB1 | P | Ser788;Ser795 | S(ph)PYKFPSS(ph)PLR | A431 | Dasatinib | 9.141 | - | |
| P06400 | RB1 | P | Ser780;Ser788;Ser795 | TNILQYASTRPPTLS(ph)PIPHIPRS(ph)PYKFPSS(ph)PLR | A431 | Gefitinib | 8.0046 | - | |
| P06400 | RB1 | P | Ser795 | FPSS(ph)PLR | A431 | Gefitinib | 5.4001 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
